Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer

Irene Romayor1, Marina Luque García-Vaquero2, Joana Márquez1

  • 1Department of Cell Biology and Histology, School of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.

The Breast Journal
|June 17, 2022
PubMed

Insights

Discoidin domain receptor 2 (DDR2) is upregulated in breast carcinoma (BC), promoting protumoral responses. DDR2 expression correlates with altered tumor microenvironment (TME) cells, suggesting it as a poor prognostic factor in BC.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Discoidin domain receptor 2 (DDR2) plays a role in cancer cell signaling and tumor microenvironment (TME) modulation.
  • The specific relationship between DDR2 expression and TME cell infiltration in breast carcinoma (BC) is not well understood.

Purpose of the Study:

  • To investigate the correlation between intratumoral DDR2 expression and the infiltration of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) in BC.
  • To assess the association of DDR2 expression with tumor aggressiveness and patient survival in invasive BC.

Main Methods:

  • Analysis of collagen and DDR2 expression in human invasive BC samples.
  • Bioinformatic analysis to identify pathways and cell types correlated with DDR2 expression.
  • Correlation analysis of DDR2 status with tumor aggressiveness, patient survival, and TME cell infiltration (CAFs and TAMs).

Main Results:

  • DDR2 was found to be upregulated in invasive BC tumor samples.
  • Altered TME markers were significantly linked to DDR2 expression in invasive BC patients.
  • DDR2 expression correlated with increased infiltration of CAFs and TAMs.

Conclusions:

  • DDR2 expression is associated with a protumoral TME in breast carcinoma.
  • DDR2 influences stromal reaction via CAF and TAM recruitment.
  • DDR2 may serve as a prognostic biomarker for treatment response in invasive BC.